Moderna shipped 800 million doses of Covid-19 vaccine in 2021
said in a letter to shareholders on Tuesday that it had shipped around 800 million doses of its Covid-19 vaccine in 2021, which roughly matches estimates the company released at the end of the year.
In November, Moderna (ticker: MRNA) lowered its expectations for deliveries of Covid-19 vaccine doses to between 700 million and 800 million, from earlier estimates of between 800 million and 1 billion.
At the time, Moderna said the reduction in production for 2021 was due to longer delivery times for international shipments and what he called a “temporary impact of expanding filling capacity. / finishing and accelerating the marketing of the product “. The company said some deliveries that are expected to be made in 2021 will arrive in early 2022.
The letter to shareholders did not specify how many of the roughly 800 million doses shipped in 2021 were primary doses and how many were recalls. Moderna’s booster dose is half of its main dose. In its November results presentation, the company said the dose capacity of 700 to 800 million for 2021 was based on a primary dose of 100 micrograms.
Moderna did not immediately respond to a request for comment on the letter to shareholders.
Moderna shares fell 7.5% on Monday, amid a liquidation of stocks of Covid-19 vaccines. The stock had a rough end in 2021, falling 34% from early October to the end of the year. Of the 18 analysts that FactSet tracks with ratings on the stock, seven give it a buy or overweight rating, while six give it a keep rating and five give it a sell or underweight rating.
Moderna shares were down 3.6% to $ 226.56 on recent trading. the
was up 0.3%.
In early December, the company reported what it called positive data from an experimental flu vaccine, but that pushed stocks down. While the candidate influenza vaccine dramatically increased antibody responses to the two most important influenza strains, the antibody response it elicited appeared to be similar to
‘s (SNY) Fluzone HD.
Write to Josh Nathan-Kazis at [email protected]